Dr. Jason Zhu from Henlius to Deliver Keynote at JPM 2026 Conference

Henlius CEO Dr. Jason Zhu to Present at JPM 2026 Conference

The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, USA. This prestigious event, recognized as one of the largest and most influential healthcare investment conferences globally, will see Dr. Jason Zhu, the CEO of Henlius (2696.HK), deliver a keynote address on January 15 (PST).

J.P. Morgan Healthcare Conference serves as a crucial platform that showcases the latest innovations and capital trends in the pharmaceutical and healthcare sectors. With over 8,000 participants expected, including industry leaders, rapidly growing startups, technology innovators, and global investors, attendees will have the opportunity to explore pioneering developments and collaborative opportunities.

During his presentation, Dr. Zhu will outline Henlius's key competencies developed throughout its international journey. He plans to unveil updates on the company’s innovative product line and cutting-edge technology platforms, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), while presenting Henlius's strategic vision for the next five years. Henlius, which has transitioned from an early-stage biotechnology firm into a large-scale biopharmaceutical company, currently operates on a global scale with a well-established international presence.

Prominently, Henlius has dedicated teams focused on clinical development, operations, and regulatory affairs in key markets such as the United States and Japan. This allows for independent execution of clinical trials and direct interactions with global regulatory authorities to expedite localized development and market access. Furthermore, the company's commercial manufacturing facilities have secured GMP certifications across China, the EU, and the United States, supported by a global supply network spanning six continents.

Through coordinated advancement of differentiated innovation assets and diverse technology platforms, Henlius is enhancing its global market presence while forging long-term strategic partnerships with leading multinational pharmaceutical companies. This approach fosters a sustainable and scalable global development model.

Looking ahead, Henlius remains dedicated to addressing unmet patient needs worldwide. By closely collaborating with global capital markets and industry partners, the company aims to further bolster its global innovation and operational capabilities. The vision is to establish a globally competitive and patient-centric biopharmaceutical entity that provides affordable and high-quality biological medications to patients globally.

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company committed to delivering innovative, affordable, and high-quality biological medicines worldwide, particularly focused on oncology, autoimmune diseases, and ophthalmology. To date, the company has received marketing approval for 10 products across various countries and regions, with five marketing applications currently under review in China and the EU, respectively. Since its founding in 2010, Henlius has developed an integrated biopharmaceutical platform characterized by high efficiency and innovation throughout the product lifecycle, encompassing R&D, manufacturing, and commercialization.

The company boasts a global innovation center and state-of-the-art commercial manufacturing facilities in Shanghai, certified by GMP standards from China, the EU, and the USA. Henlius has proactively developed a diversified and high-quality product portfolio encompassing approximately 50 molecules and continues to explore immuno-oncology combination therapies, leveraging its patented anti-PD-1 monoclonal antibody HANSIZHUANG as a cornerstone. Current offerings include HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), the world's first anti-PD-1 mAb for first-line treatment of small cell lung cancer; HANQUYOU (trastuzumab, marketed as HERCESSI™ in the USA and Zercepac® in Europe), a biosimilar mAb developed in China and approved in multiple markets; and several others including Hanlikang (rituximab), the first biosimilar developed in China, denosumab Bildyos®, and pertuzumab Poherdy®.

Additionally, Henlius has conducted over 30 clinical studies for 19 products, enhancing its presence in both major and emerging markets. For more details about Henlius, please visit Henlius Website or connect with us on LinkedIn.